Gensight Biologics (LTS:0RIM) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RIM Gensight Biologics SA LTS:0RIM
14 GF Score
Price €0.12
GF Value €0.04
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Gensight Biologics Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

LTS:0RIM
14GF Score
Gensight Biologics SA LTS:0RIM
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gensight Biologics (LTS:0RIM) Overvalued in 2026?

Based on GuruFocus' analysis, Gensight Biologics stock appears to be overvalued. The current stock price of €0.12 is trading 204.5% above its estimated GF Value™ of €0.04. GuruFocus considers Gensight Biologics to be Significantly Overvalued.

Key valuation signals for LTS:0RIM:

  • Interest Received:
  • GF Value™: €0.04 vs. price of €0.12 (204.5% above fair value)
  • GF Score™: 14/100 with 8 warning signs

No single metric tells the full story. See the LTS:0RIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gensight Biologics Business Description

Address 74, rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
14GF Score

Get the complete analysis for LTS:0RIM

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.12
Price
€0.04
GF Value